# A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

> **NCT01462162** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 122 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01462162
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462162, "A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01462162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*